AR122989A1 - Formulación farmacéutica tópica estable que contiene un inmunosupresor para el tratamiento de afecciones dermatológicas - Google Patents

Formulación farmacéutica tópica estable que contiene un inmunosupresor para el tratamiento de afecciones dermatológicas

Info

Publication number
AR122989A1
AR122989A1 ARP210101999A ARP210101999A AR122989A1 AR 122989 A1 AR122989 A1 AR 122989A1 AR P210101999 A ARP210101999 A AR P210101999A AR P210101999 A ARP210101999 A AR P210101999A AR 122989 A1 AR122989 A1 AR 122989A1
Authority
AR
Argentina
Prior art keywords
treatment
immunosuppressant
pharmaceutical formulation
formulation containing
topical pharmaceutical
Prior art date
Application number
ARP210101999A
Other languages
English (en)
Inventor
Raymond Ruzhong Chen
Amanda Patrice Surajhie Samuel
Todd Christopher Zelesky
Xiang Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR122989A1 publication Critical patent/AR122989A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Abstract

Una formulación tópica estable y resistente al amarilleo para el tratamiento de una afección dermatológica incluye un inhibidor de JAK en una emulsión de aceite en agua; vaselina blanca en una cantidad de aproximadamente 10% en peso; menos de aproximadamente 0,7 ppm de butilhidroxitolueno (BHT) en peso; alcohol oleílico en una cantidad de aproximadamente 2% en peso; y un agente antimicrobiano. Reivindicación 4: La formulación tópica de la reivindicación 1, en la que el inhibidor de JAK comprende ((S)-2,2-difluorociclopropil)-((1R,5S)-3-(2-((1-metil-1H-pirazol-4-il)amino)pirimidin-4-il)-3,8-diazabiciclo[3.2.1]-octan-8-il)metanona.
ARP210101999A 2020-07-17 2021-07-15 Formulación farmacéutica tópica estable que contiene un inmunosupresor para el tratamiento de afecciones dermatológicas AR122989A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063053060P 2020-07-17 2020-07-17

Publications (1)

Publication Number Publication Date
AR122989A1 true AR122989A1 (es) 2022-10-19

Family

ID=77043001

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101999A AR122989A1 (es) 2020-07-17 2021-07-15 Formulación farmacéutica tópica estable que contiene un inmunosupresor para el tratamiento de afecciones dermatológicas

Country Status (8)

Country Link
US (1) US20230277537A1 (es)
EP (1) EP4181874A1 (es)
JP (1) JP2022019648A (es)
AR (1) AR122989A1 (es)
AU (1) AU2021308340A1 (es)
CA (1) CA3189561A1 (es)
TW (1) TWI786724B (es)
WO (1) WO2022013708A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
EP2574168B9 (en) * 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
NO2721710T3 (es) 2014-08-21 2018-03-31
US20190060311A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo

Also Published As

Publication number Publication date
TW202207936A (zh) 2022-03-01
JP2022019648A (ja) 2022-01-27
AU2021308340A1 (en) 2023-02-23
US20230277537A1 (en) 2023-09-07
CA3189561A1 (en) 2022-01-20
WO2022013708A1 (en) 2022-01-20
EP4181874A1 (en) 2023-05-24
TWI786724B (zh) 2022-12-11

Similar Documents

Publication Publication Date Title
US11872218B2 (en) Compositions and methods for treating diseases of the nail
Kyle et al. Topical therapy for fungal infections
JP4828563B2 (ja) 水虫治療用外用剤
CN105920603B (zh) 勃起功能障碍和其它适应症的治疗
US20140004176A1 (en) Delivery of treatments transdermally for fungal infections and other indications
WO2016010984A2 (en) Compositions and methods for treating rosacea
US8815953B2 (en) Formulations of vitamin K analogs for topical use
MXPA05010114A (es) Revestimiento anti-fungico para unas y metodo de uso.
NZ571819A (en) External pharmaceutical composition comprising luliconazole and either N-methyl-2-pyrrolidone, propylene carbonate or crotamiton
BR0311414A (pt) Agente terapêutico para uma bexiga hiperativa
US9289495B2 (en) Systems and methods for treatment of allergies and other indications
US20220110860A1 (en) Transdermal formulations
US20030130225A1 (en) Novel methods of treating local fungal and bacterial infections
CA2528431A1 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
AR122989A1 (es) Formulación farmacéutica tópica estable que contiene un inmunosupresor para el tratamiento de afecciones dermatológicas
US20060182790A1 (en) Dermal medicaments application enhancer
JP2007008893A (ja) 抗真菌医薬組成物
AU2017272269A1 (en) Excipient system for topical delivery of pharmaceutical agents
WO2005032530A1 (ja) 外用医薬組成物
JP4692280B2 (ja) 抗真菌剤組成物
JP2006232853A (ja) 抗真菌組成物
JP5980488B2 (ja) 口角炎の治療用医薬組成物
US20220175732A1 (en) Treatment of rosacea with topical combination compositions
BR112023018932A2 (pt) Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular
CN117545478A (zh) 用于治疗慢性疼痛的透皮药物制剂